Tysabri and Pelvic inflammatory disease - a phase IV clinical study of FDA data

Summary:

Pelvic inflammatory disease is reported as a side effect among people who take Tysabri (natalizumab), especially for people who are 50-59 old, have been taking the drug for 1 - 6 months also take Claritin, and have Atrial fibrillation/flutter.

The phase IV clinical study analyzes which people have Pelvic inflammatory disease when taking Tysabri. It is created by eHealthMe based on reports of 220,870 people who have side effects when taking Tysabri from the FDA, and is updated regularly.

What is Tysabri?

Tysabri has active ingredients of natalizumab. It is often used in multiple sclerosis. eHealthMe is studying from 221,369 Tysabri users. Check the latest studies of Tysabri.

What is Pelvic inflammatory disease?

Pelvic inflammatory disease is found to be associated with 176 drugs and 293 conditions by eHealthMe. Check the latest studies of Pelvic inflammatory disease.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

220,870 people reported to have side effects when taking Tysabri.
Among them, 13 people (0.01%) have Pelvic inflammatory disease.

Could Tysabri cause Pelvic inflammatory disease?

Among these 13 people:

How long have people been on Tysabri when they have Pelvic inflammatory disease? *

What is the age of people who have Pelvic inflammatory disease when taking Tysabri? *

What are other drugs people take besides Tysabri? *

What are other side effects people have besides Pelvic inflammatory disease? *

Female Genital Tract Fistula (passage in genital tract of female): 6 people, 46.15%
Diverticular Perforation (serious gastrointestinal condition in which the intestine's walls are perforated): 6 people, 46.15%
Weakness: 6 people, 46.15%
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall): 5 people, 38.46%
Cognitive Disorder (mental health disorders affects learning, memory, perception, and problem solving): 5 people, 38.46%
Post Procedural Complication: 5 people, 38.46%
Intestinal Obstruction: 5 people, 38.46%
Peridiverticular Abscess: 4 people, 30.77%
Gastrointestinal Perforation (hole in the digestive tract): 4 people, 30.77%
Constipation: 2 people, 15.38%

What are the existing conditions these people have? *

Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 4 people, 30.77%
Stress And Anxiety: 1 person, 7.69%
Pain: 1 person, 7.69%
High Blood Cholesterol: 1 person, 7.69%
Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 7.69%
Endometriosis (appearance of endometrial tissue outside the uterus and causing pelvic pain): 1 person, 7.69%
Cardiac Disorder: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Tysabri and have Pelvic inflammatory disease?

- Check whether Pelvic inflammatory disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tysabri:

Tysabri (221,369 reports)

Browse all side effects of Tysabri:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pelvic inflammatory disease:

Pelvic inflammatory disease (176 drugs)

Browse all the conditions that are associated with Pelvic inflammatory disease:

Pelvic inflammatory disease (293 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on natalizumab (the active ingredients of Tysabri) and Tysabri (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.